David Stump
Vermögen: 274 258 $ am 30.09.2026
Vermögen: 274 258 $ am 30.09.2026
Dr. David C.
Stump, MD, is an Independent Director at REGENXBIO, Inc. and an Independent Director at MacroGenics, Inc. He is on the Board of Directors at REGENXBIO, Inc., MacroGenics, Inc. and Earlham College.
Dr. Stump was previously employed as an Independent Director by Portola Pharmaceuticals LLC, an Independent Director by Dendreon Corp., an Independent Director by Sunesis Pharmaceuticals, Inc., a Trustee by Adventist HealthCare, Inc., an Executive Vice President-Research & Development by Human Genome Sciences, Inc., a Vice President-Clinical Research by Genentech, Inc., and an Associate Professor by University of Vermont.
He received his undergraduate degree from Earlham College and a doctorate degree from Indiana University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
REGENXBIO, INC. 0,04 % | 29.05.2026 | 28 861 ( 0,04 % ) | 217 323 $ | 30.09.2026 |
MACROGENICS, INC. 0,02 % | 19.05.2026 | 14 750 ( 0,02 % ) | 56 935 $ | 30.09.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| MACROGENICS, INC. | Direktor/Vorstandsmitglied | 19.09.2013 |
| REGENXBIO INC. | Direktor/Vorstandsmitglied | 15.10.2015 |
Earlham College
Earlham College Other Consumer ServicesConsumer Services Functions as a College/University | Direktor/Vorstandsmitglied | 22.02.2010 |
| Unternehmen | Position | Ende |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 24.02.2021 |
| PORTOLA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 01.07.2020 |
| DENDREON CORPORATION | Direktor/Vorstandsmitglied | 10.06.2015 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Provides pharmaceutical and diagnostic products | Technik-/Wissenschafts-/F&E-Leiter | 01.12.2012 |
Adventist HealthCare, Inc.
Adventist HealthCare, Inc. Medical/Nursing ServicesHealth Services Provides health care services | Direktor/Vorstandsmitglied | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 11 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Provides pharmaceutical and diagnostic products | Health Technology |
Dendreon Corp.
Dendreon Corp. Medical SpecialtiesHealth Technology Discovers, develops and commercializes novel products for the treatment of cancer | Health Technology |
Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops oncology therapeutics for treatment of solid and hematologic cancers | Health Technology |
Portola Pharmaceuticals LLC
Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of novel therapeutics | Health Technology |
REGENXBIO, Inc.
REGENXBIO, Inc. Pharmaceuticals: MajorHealth Technology Develops gene therapy | Health Technology |
MacroGenics, Inc.
MacroGenics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes antibody-based therapeutics for the treatment of cancer | Health Technology |
Earlham College
Earlham College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Indiana University
Indiana University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Vermont
University of Vermont Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Adventist HealthCare, Inc.
Adventist HealthCare, Inc. Medical/Nursing ServicesHealth Services Provides health care services | Health Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen